. Author manuscript; available in PMC: 2013 Jan 1.

Published in final edited form as: Expert Rev Clin Pharmacol. 2012 Mar;5(2):113–123. doi: 10.1586/ecp.12.2

Table 3.

Efficacy of mesalamine in inducing remission of ulcerative colitis.

Formulation	End point	Response rate
Lialda^®	Clinical (UCDAI ≤1) and endoscopic remission (sigmoidoscopy score reduction of 1 or more points from baseline)	8-week complete mucosal healing rate of 32% in MMX mesalamine groups (either 2.4 g/day or 4.8 g/day) compared with 16% on placebo
Asacol^®	Endoscopy score of 0 or 1: mucosal healing	At 6 weeks, 80% of patients achieved mucosal healing on 4.8 g/day, while 68% of those on 2.4 g/day achieved this
Pentasa^®	Clinical and endoscopic remission	At 8 weeks, 44 and 48% of patients receiving 2 and 4 g achieved remission by endoscopy, compared with 31% on placebo
Apriso^®/Salofalk^®	Clinical and endoscopic remission	After 8 weeks, patients receiving 3 g daily had remission rates of 66%, similar to those receiving 4.5 g daily (56%)

MMX: Multi Matrix System; UCDAI: Ulcerative Colitis Disease Activity Index.

Data taken from [28].